SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes ; volume:11 ; number:12 ; day:29 ; month:9 ; year:2020 ; pages:2757-2774 ; date:12.2020
Diabetes therapy ; 11, Heft 12 (29.9.2020), 2757-2774, 12.2020
- Urheber
-
Wheeler, David C.
James, June
Patel, Dipesh
Viljoen, Adie
Ali, Amar
Evans, Marc
Fernando, Kevin
Hicks, Debbie
Milne, Nicola
Newland-Jones, Philip
Wilding, John
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-020-00930-x
- URN
-
urn:nbn:de:101:1-2020121818373271477508
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wheeler, David C.
- James, June
- Patel, Dipesh
- Viljoen, Adie
- Ali, Amar
- Evans, Marc
- Fernando, Kevin
- Hicks, Debbie
- Milne, Nicola
- Newland-Jones, Philip
- Wilding, John
- SpringerLink (Online service)
Ähnliche Objekte (12)
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Direct cardiac effects of SGLT2 inhibitors
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease
SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Direct cardiac effects of SGLT2 inhibitors
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease
SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Direct cardiac effects of SGLT2 inhibitors
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease
SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors